Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Complete | ||
| Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
| XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Forxiga | dapagliflozin | Chronic kidney disease | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
| Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | dapagliflozin | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 17, 2024